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OBJECTIVE—Despite promising results from studies on mouse models, intranasal insulin
failed to prevent or delay the development of type 1 diabetes in autoantibody-positive children
with HLA-conferred disease susceptibility. To analyze whether the insulin dose was inadequate
toelicitanimmunomodulatoryresponse,wecomparedthechangesobservedininsulinantibody
(IA) afﬁnity and isotypes after treatment with nasal insulin or placebo.
RESEARCH DESIGN AND METHODS—Ninety-ﬁve children (47 in the placebo group
and 48 in the insulin group of the total of 224 children randomized for the trial) with HLA-
conferred susceptibility to type 1 diabetes derived from the intervention arm of the Finnish
Type 1DiabetesPrediction andPrevention studywere includedintheseanalyses. Bloodsamples
drawn before or at the beginning of the treatment and after treatment for 3 and 6 months were
analyzed for IA afﬁnity and isotype-speciﬁc IAs (IgG1–4, IgA, IgM, and IgE).
RESULTS—IgG3- and IgA-IA levels (P = 0.031 and 0.015, respectively) and the number of
IgG3-IA–positive subjects (P=0 .0 22)wer es ig ni ﬁcantlyhigher at 6 months after theinitiation of
the treatment in the insulin group. No signiﬁcant differences were observed between the two
groups in IA afﬁnity or other IA isotypes.
CONCLUSIONS—The insulin dose administered induced a modest change in the IA isotype
proﬁle. The lack of impact of nasal insulin on IA afﬁnity implies that the immune response of
study subjects was already mature at the beginning of the intervention.
Diabetes Care 34:1383–1388, 2011
N
umerous studies have demon-
strated that the prophylactic ad-
ministration of insulin via various
routes prevents development of autoim-
mune diabetes in NOD mice and other
animal models of type 1 diabetes (1–3).
The beneﬁcial effect of insulin is per-
ceived to be attributed to the promotion
of immunologic tolerance, alterations in
metabolism (i.e., exogenous insulin re-
ducing the metabolic burden of the
b-cells), or a combination of both mech-
anisms (3,4). Despite promising results
from pilot studies (5), subcutaneously
(6),orally(7),andintranasally(8)admin-
istered insulin failed to prevent type 1
diabetes in large clinical trials in humans.
Several explanations for these failures
have been proposed, including inade-
quate insulin dose, incorrect timing of
the intervention, and inefﬁciency of in-
sulin administration as a prophylactic
measure for human type 1 diabetes.
Increasing afﬁnity of an antibody to
the antigen reﬂects the maturation of
the immune response and, thus, could
be a valuable tool when assessing the
pathogenesis of autoimmune diseases.
Accordingly, the afﬁnity of insulin auto-
antibodies (IAAs) has been proposed to
provide a means to differentiate between
progressive and nonprogressive or slowly
progressiveb-cellautoimmunity,because
high IAA afﬁnity has been demonstrated
to increase the risk of type 1 diabetes in
schoolchildren from the general popula-
tion and in adults and adolescents having
ﬁrst-degree relative(s) with type 1 dia-
betes (9,10). However, among young
children with HLA-conferred susceptibil-
ity to type 1 diabetes, IAA afﬁnities were
already high at the time of seroconver-
sion,and theafﬁnityfailedtodifferentiate
between a progressing and a nonprog-
ressing or slowly progressing disease pro-
cess (11). Maturation of an immune
response is also reﬂected by changes in
the isotype proﬁle of the antibody re-
sponse. According to a previous study in
children with HLA-deﬁned disease pre-
disposition, high titers of IgG1- and
IgG3-IAA are associated with increased
risk of type 1 diabetes, whereas a weak
or failing IgG3 response seems to provide
relative protection from the disease (12).
Because the reasons for the failure of
the nasal insulin treatment in the pre-
vention of type 1 diabetes remain elusive
(8), we decided to characterize its effects
on the insulin-speciﬁca n t i b o d yp r o ﬁles.
Accordingly, we determined the insulin
antibody (IA) afﬁnities and isotypes from
95childrenwhoparticipatedinthepreven-
tion trial with intranasal insulin (47 in the
place bogr oupan d48inth ein sul ingroup)
in the Finnish Type 1 Diabetes Prediction
and Prevention (DIPP) Study (8).
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ORIGINAL ARTICLERESEARCH DESIGN AND
METHODS—The participants in this
study were derived from the intervention
arm of the Finnish DIPP Study (8). In the
DIPPStudy,childrenwithHLA-conferred
susceptibility to type 1 diabetes were ob-
served from birth for the appearance of
diabetes-associated autoantibodies (13).
Measurement of islet cell autoantibodies
( I C A s )w a su s e da st h eﬁr s ts t e pi nt h e
autoantibody screening. If a subject sero-
converted to ICA positivity or developed
diabetes, all his/her previous samples
were analyzed also for IAA, glutamic acid
decarboxylase (GADA), and islet antigen-2
(IA-2A). Children aged .1 year with
persistent positivity for multiple ($2)
autoantibodies were invited into the in-
tervention arm of the DIPP Study com-
prising a randomized, double–blinded,
and placebo–controlled trial with nasally
administrated insulin (registered with
clinicaltrials.gov, Clinical trial reg. no.
NCT0022361) (8). In brief, participants
received either recombinant human
short-acting insulin (Actrapid in its
regular buffer; NovoNordisk, Bagsvaerd,
Denmark) or the buffer alone. The insulin
dose administered once daily was 1 inter-
national unit (IU)/kg, rounded because of
practical reasons to multiples of 10 IU
(maximum 60 IU per day), divided evenly
between the nostrils, and given just before
breakfast. The preparations were donated
by the manufacturer and packed in me-
tered nasal applicators (VP/100S; Beresol,
Gävlinge, Sweden). For the current study,
95 children (47 in the placebo group and
48 in the insulin group) of a total 224
randomized subjects in the original trial
(109 in the placebo group and 115 in the
insulingroup)wereselectedonthebasisof
availability of blood samples at 0, 3, and 6
months after the start of the intervention
and on testing positive for IAs in at least
one of these samples. The baseline charac-
teristics of the study subjects in the current
study and those included in the inter-
vention arm of the DIPP Study (8) are
presented in Supplementary Table 1.
Laboratory methods
Screening for HLA-DQB1–associated risk
genotypes for type 1 diabetes (the high-
risk genotype HLA DQB1*02/*0302 and
the moderate-risk genotypes HLA
DQB1*0302/x; x *02, *0301, *0602, or
*0603 conferring average risks of 8 and
3%, respectively) (14,15) was performed
on cord blood samples by time-resolved
triple-label hybridization (16). The INS
223Hph1 polymorphism was analyzed
usingPCRandalanthanide-labeledoligo-
nucleotide hybridization method, as de-
scribed previously (16).
Antibody measurements were per-
formed on serum or plasma samples,
depending on availability, ICA with im-
munoﬂuorescence (17) and IAA (and IA),
GADA, and IA-2A with speciﬁcr a d i o -
binding assays (18–20). The cutoff values
for ICA, IAA, GADA, and IA-2A positivity
were 2.5 Juvenile Diabetes Foundation
units, 3.48, 5.36, and 0.43 relative units
(RU), respectively. Cutoff values for the
IAA, GADA, and IA-2A assays were based
on the 99th percentile of more than 370
healthy Finnish children and adolescents.
All initially ICA-positive samples were re-
tested to conﬁrm positivity, as were the
samples with IAA, GADA, and IA-2A lev-
els between the 97th and 99.5th percen-
tiles. On the basis of the 2005 Diabetes
Autoantibody Standardization Program
Workshop, the disease sensitivity values
fortheIAA,GADA,andIA-2Aassayswere
58,82,and 72%, and the diseasespeciﬁc-
ity values were 98, 96, and 100%, respec-
tively.
IAA and IA afﬁnity was measured by
radiobinding of 0.159 nmol/L labeled
mono
125I (TyrA14) human recombinant
insulin (Amersham, GE Healthcare,
Buckinghamshire, UK; activity 2,000
Ci/mmol) after competition with eight in-
creasing concentrations (between 1.2 3
10
212 and 1.75 3 10
24 mol/L) of unla-
beledhuman recombinantinsulin(Roche
Diagnostics, Mannheim, Germany). The
assay was modiﬁed from that described
by Achenbach et al. (9). Samples were
measured in duplicates, and the total vol-
ume per well was 30 mL. After precipita-
tion of the immune complexes, the
amount of bound labeled insulin was
measuredwithaliquidscintillationdetec-
tor (1450 MicroBeta Trilux; Perkin Elmer
Life Sciences, Turku, Finland), and the
results were given as counts per minute.
Values for the half-maximal inhibitory
concentration (IC50) and the dissociation
constant (Kd) were calculated by using
Prism 5.0 (GraphPad Software, Inc., San
Diego, CA), and IA afﬁnity was given as
the reciprocal of the Kd value (L/mol).
Analyzing high-afﬁnity IA containing
samples was not always straightforward.
For 21 samples (of 272 samples in total)
with high afﬁnities, we had to extrapo-
late the afﬁnity from the linear correla-
tion between log Kd and log IC50 values
(R
2 = 0.955, P , 0.001) obtained for
high-afﬁnity samples (10
10 L/mol ,
afﬁnity , 10
11 L/mol) that could be
reliably determined. Samples from one
study subject consistently showed char-
acteristics of two-site binding and were
eventuallyexcludedfromtheanalysisbe-
cause of difﬁculties in determining reliable
values, and samples from one subject in-
cluded in the study were lost before mea-
suring afﬁnity. In addition, samples from
three subjects demonstrated unreliable
competitive binding curves despite three
separate measurements and had to be ex-
cluded from the analysis. Despite these ad-
justments, the balance between the study
groups was maintained with 45 subjects in
both the placebo and insulin groups.
Isotype- and subclass-speciﬁcI A s
were analyzed as described previously
(12). Brieﬂy, 5 mL serum was incubated
with mono
125I (TyrA14) human insulin
and precipitated with biotinylated isotype-
and subclass-speciﬁc monoclonal anti-
bodieslinkedtostreptavidinagarose(Pierce
andWarriner,Chester,UK).Thebiotiny-
lated monoclonal anti-human antibodies
and anti-rat IgM were obtained from BD
PharMingen (San Diego, CA), with the ex-
ception of anti-human IgG3, which was
from Southern Biotech (Birmingham, AL).
The results were expressed as SD scores
as deﬁned previously (12), and the cutoff
level for positivity was set at an SD score
of 3 SD.
Data analysis
SPSS 17.0 statistical software package
(SPSS Inc., Chicago, IL) was used for the
statistical analysis. The variables ana-
lyzedhadskeweddistributions,andnon-
parametric tests were primarily used, i.e.,
Wilcoxon signed rank test for paired
variables and Mann–Whitney U test for
independent variables. In addition, the x
2
test was used when applicable. Two-tailed
statistical signiﬁcance was set at P , 0.05.
With 40 subjects in each group, we would
have already had a statistical power of
80% to identify afﬁnity differences of
the magnitude similar to that described
between risk subjects who later devel-
oped type 1 diabetes and those who re-
mained unaffected in previous studies
(9,10). Bonferroni correction for multiple
comparisons was not applied in the data
analysis.
RESULTS—Thebaselinecharacteristics
of the study subjects are presented in
Supplementary Table 2. Mean age and
sex distribution were relatively uniform
in the placebo and insulin groups. In ad-
dition, the median titers and range for
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IAA, GADA, and IA-2A) at baseline are
given. No signiﬁcant changes in the levels
or number of subjects positive for these
autoantibodies were seen between the
treatment groups before the start of treat-
ment or 3 and 6 months later (data not
shown).
IA levels did not change signiﬁcantly
during the 6-month follow-up (Fig. 1A).
More speciﬁcally, at the beginning of the
treatment with either placebo or insulin,
the median IAA levels for placebo and in-
sulin groups were 11.3 RU (range 1.4–
293.3) and 9.8 RU (range 0.7–166.0),
respectively (P = 0.222). At the second
sampling (3monthsaftertheintervention
started), median IA levels for placebo and
insulin groups were 12.2 RU (range 0.7–
233.2) and 9.0 RU (range 1.4–358.4, P =
0.245), respectively, and at 6 months, the
median IA level was 10.1 RU (range 0.0–
120.1) in the placebo group and 9.5 RU
(range1.4–187.9,P=0.774)intheinsulin-
treated group. Even at the beginning of
the intervention, the IAA afﬁnities were
high in both groups, with a median afﬁn-
ity in the placebo and insulin groups of
6.12310
9and7.01310
9L/mol,respec-
tively (P = 0.649). After the administra-
tion of placebo or insulin, the IA afﬁnity
remained essentially at the same level
throughout the 6-month follow-up, and
no signiﬁcant differences between the
two groups were evident (Fig. 1B). HLA-
conferred risk (mediate vs. high risk) or
insulin gene polymorphism (AA, AT, or
TT)ofthestudysubjectsdidnothaveany
signiﬁcant impact on IA afﬁnity during
the intervention (data not shown).
Data on titers of various IA subclasses
and isotypes are presented in Table 1. In
brief, statistically signiﬁcant differences
between the treatment groups were ob-
served only for IgG3- and IgA-IAs at
6 months when children treated with in-
sulin had higher antibody levels (P =
0.031 and 0.015, respectively). However,
the titers of IgA-IA were generally low
with only two subjects (4.9%) testing
positive for IgA-IA in the placebo group
and three subjects (5.9%) testing positive
in the insulin group at 6 months after the
initiation of the intervention (Fig. 2C, P =
0.704). In contrast, the difference be-
tween the placebo and insulin groups re-
mained signiﬁcant for IgG3-IA when
autoantibody positivity was considered.
Accordingly, 6 months after beginning
the administration of intranasal insulin,
16 children (36.4%) tested positive for
IgG3-IA in the insulin group compared
with six children (14.6%) in the placebo
group(Fig.2C,P=0.022).Spaghettiplots
illustrating changes in IgG3-IAs for all
study subjects positive for IgG3 at some
of the three time points are presented
in Fig. 3, and the baseline characteris-
tics of these individuals are shown in
Supplementary Table 3. In the placebo
group, IgG3-IAs decreased in 9 of 14 pa-
tients (Fig. 3A), whereas IgG3-IAs
increased in 6 of 19 patientsin theinsulin
group (Fig. 3B). Accordingly, part of the
observed difference in IgG3-IAs at
Figure 1—A: IAA levels in RU. B:I A Aa f ﬁni-
ties in L/mol. The samples drawn before and at
;3 and 6 months after the start of the in-
tervention are depicted by circles, squares,a n d
triangles, respectively. Open symbols denote
children in the placebo group, and ﬁlled sym-
bols denote children in the insulin group.
Horizontal lines represent medians. Note the
logarithmic scale on the y axis.
Table 1—Results from the analyses of IAA isotypes, given as medians (range)
Placebo group Insulin group P
Median IgG1 titer, SDS (months)
0 5.5 (0.0–136.1) 3.2 (0.0–120.5) 0.470
3 5.9 (0.0–99.3) 4.2 (0.0–80.8) 0.361
6 3.4 (0.0–106.8) 3.4 (0.0–49.5) 0.470
Median IgG2 titer, SDS (months)
0 0.5 (0.0–84.9) 0.4 (0.0–95.3) 0.639
3 1.0 (0.0–121.3) 0.7 (0.0–96.3) 0.465
6 1.2 (0.0–58.3) 1.2 (0.0–47.2) 0.893
Median IgG3 titer, SDS (months)
0 0.3 (0.0–166.9) 0.5 (0.0–100.1) 0.849
3 0.3 (0.0–74.9) 0.1 (0.0–23.6) 0.844
6 0.0 (0.0–50.3) 0.3 (0.0–61.5) 0.031
Median IgG4 titer, SDS (months)
0 1.2 (0.0–46.8) 0.7 (0.0–42.7) 0.714
3 1.4 (0.0–48.6) 0.7 (0.0–35.0) 0.614
6 0.7 (0.0–30.4) 0.6 (0.0–35.4) 0.957
Median IgA titer, SDS (months)
0 0.0 (0.0–2.3) 0.0 (0.0–6.0) 0.694
3 0.2 (0.0–1.9) 0.0 (0.0–4.8) 0.218
6 0.0 (0.0–6.9) 0.0 (0.0–28.4) 0.015
Median IgE titer, SDS (months)
0 0.2 (0.0–2.2) 0.0 (0.0–2.5) 0.596
3 0.0 (0.0–2.5) 0.0 (0.0–2.5) 0.610
6 0.5 (0.0–6.0) 0.1 (0.0–3.1) 0.410
Median IgM titer, SDS (months)
0 0.0 (0.0–17.8) 0.0 (0.0–5.3) 0.194
3 0.0 (0.0–13.5) 0.0 (0.0–2.8) 0.401
6 0.0 (0.0–10.7) 0.2 (0.0–4.5) 0.428
Boldface type indicates signiﬁcant P values. SDS, SD score.
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the placebo group but also to a genuine
increase in the insulin group. In keeping
with previous reports(12),the study sub-
jects who were diagnosed with type 1
diabetes during the intervention had
signiﬁcantly higher IA, IgG1-IA, and
IgG3-IA levels at 0, 3, and 6 months, re-
spectively,afterthestartoftheintervention
than those who remained nondiabetic
(data not shown).
CONCLUSIONS—Several explana-
tions for the failuresexperienced inclinical
trials using insulin as a preventive mea-
sure for type 1 diabetes during pre-
diabetes have been proposed. The most
obvious one is an inadequate amount of
insulin administered for the induction of
an immunomodulatory response. In the
intervention arm of the DIPP Study, the
intranasally delivered insulin dose was
chosen to correspond to the approxi-
mate daily physiologic insulin need, i.e.,
1 unit/kg, when insulin is given parenter-
ally (8). The dose applied was four times
the subcutaneously administered dose
used in the Diabetes Prevention Trial (6).
A blinded crossover trial showed that
1.6 mg (;46 IU) recombinant insulin ad-
ministered to the nasal mucosa daily for
10 days and then twice per week for a total
of 6 months induced an increase in IA
levels compared with placebo (21). We
could not conﬁrm this ﬁnding because
our results indicated no signiﬁcant
changes in IA levels after the initiation
of intranasal insulin treatment (Fig. 1A).
Variable IA responses to exogenous insulin
are probably attributed to the result of dif-
ferences in patient populations and in the
stage of prediabetes among the study sub-
jects. More speciﬁcally, Harrison et al. (21)
recruited ﬁrst-degree relatives of patients
with type 1 diabetes who tested positive
for at least one autoantibody (IAA, GADA,
or IA-2A), whereas the inclusion criteria
for the intervention arm of the DIPP Study
required positivity for at least two auto-
antibodies. It is possible that the subjects
in the current study had a more mature
immune response to insulin at the begin-
ning of the intervention and thus did not
show any increase in IA levels. However,
we demonstrate that the intranasal insulin
dose delivered in the DIPP Study did
induce a detectable change in IA character-
istics and, accordingly, was adequate to
elicit a modest immunomodulatory effect.
More speciﬁcally, insulin treatment in-
creased the titers of IgG3- and IgA-IAs
after 6 months of treatment compared
with the placebo group (Table 1). How-
ever, the levels of IgA-IA were very low in
both treatment groups, and when the
number of IgA-IA–positive individuals
was compared, no signiﬁcant difference
was seen between the two groups. For
IgG3-IAs, the observed increase was
more convincing. Children in the insulin
group were also signiﬁcantly more often
IgG3-IA–positive compared with children
receiving the placebo preparation after
6 months of treatment (Fig. 2C).
If the insulin dose is adequate and
exerts an immunologic response, the rea-
sons for ineffectiveness in the prevention
of type 1 diabetes could be incorrect
timing of the intervention during the
prediabetic phase, choice of an unrespon-
sive subgroup, or simply the fact that in-
sulin administration during preclinical
diabetes does not prevent the clinical
disease in humans. On the basis of the
present knowledge, it is not possible to
deﬁnitely rule out any of these options,
anditisalsopossiblethatthecombination
of the above explanations contributed to
the failure. In the DIPP Study, children
withHLA-conferredsusceptibilitytotype1
diabetes were under close follow-up, and
the intervention was started in subjects
who tested positive for at least two auto-
antibodies (ICA, IAA, GADA, and IA-2A).
Ouranalysisshowsthat,inthispopulation,
IAA afﬁnity was already relatively high at
the start of the intervention, and no
additional maturation of the IA response
in terms of increased afﬁnity during the
6-month follow-up was observed. It has
been demonstrated that high IAA afﬁnity
is associated with increased risk of pro-
gression to type 1 diabetes in adults and
adolescentshavingﬁrst-degreerelative(s)
with type 1 diabetes and among school-
children from the general population,
and,accordingly,wouldpresentamarker
f o rm o r ea g g r e s s i v eo ra d v a n c e di n s u l i t i s
(9,10). Along these lines, it could be ar-
gued that, in the DIPP Study, the insulin
administration was started too late in the
disease process when the immune re-
sponse to insulin was already mature.
On the other hand, the intervention
started earlier in relation to initial sero-
conversion in the DIPP Study than in
any previous trial. Previously published
data in young children with HLA-
conferred susceptibility to type 1 diabetes
showed that IAA afﬁnity was already high
at the time of seroconversion (11). Ac-
cordingly, it is questionable to draw
any conclusions about the stage of
prediabetes on the basis of IAA afﬁnity
amongsubjectsparticipatingintheDIPP
Study. Earlier initiation of the treat-
ment, i.e., before the appearance of the
ﬁrst autoantibodies, would raise signiﬁ-
cant practical and ethical issues because
the risk of clinical disease is relatively
low before seroconversion to autoanti-
bodypositivity,andsuchaneffortwould
inevitably require a higher number of
Figure2—Frequenciesforpositivityofdifferent
IAA isotypes in children receiving placebo (□)
and insulin (■) intranasally. Statistically sig-
niﬁcant differences are marked. A:I A Ai s o t y p e s
at baseline. B:I A Ai s o t y p e s;3m o n t h sf r o mt h e
startofthetreatment.C:IAAisotypes;6months
from the start of the treatment.
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